Physician profile
Mario H Gomez
NPI 1518905884
$5,373.03
in general payments reported to CMS, 2019-2025
19 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 89% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $241 · 2021: $638 · 2022: $222 · 2023: $345 · 2024: $1,243 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,588.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,287.44 | 2021-2025 | Caplyta |
| Abbvie INC. | $928.42 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $593.92 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $474.76 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $386.59 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $383.65 | 2024-2025 | Cobenfy |
| Allergan, INC. | $279.62 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $222.69 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $171.93 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Tris Pharma INC | $159.89 | 2024-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Axsome Therapeutics, INC. | $138.22 | 2023-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $128.12 | 2022-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $82.81 | 2019-2023 | Invega, Spravato, Invega Trinza |
| Alkermes, INC. | $37.44 | 2019-2021 | |
| Janssen Biotech, INC. | $27.19 | 2024 | Tremfya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $23.30 | 2024 | Rexulti |
| Eisai INC. | $20.11 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.25 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.